Immuno-Oncology | Specialty

Ramucirumab/Pembrolizumab Produces Encouraging ORR in Recurrent or Metastatic HNSCC

January 17th 2022

The addition of ramucirumab to pembrolizumab elicited an encouraging response rate when used in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

New, Updated Data Demonstrate Promising Future in Advanced Melanoma

January 14th 2022

Jeffrey S. Weber, MD, PhD, overviews the successes made in the melanoma setting in the past decade and the challenges to overcome in the future.

Immunotherapy Outcomes in HPV-Associated Head and Neck Cancer Fuel Investigative Efforts

January 14th 2022

Robert L. Ferris, MD, PhD, discusses the current standard of care for patients with head and neck cancer, the role of HPV in treatment decisions, and the need to personalize therapy for patients.

GLORIA Trial Examining NOX-A12 Plus Radiotherapy/Bevacizumab in Glioblastoma Safe to Continue Recruitment

January 11th 2022

The Data Safety Monitoring Board has determined that it is safe and appropriate to continue recruitment to the expansion arm of the phase 1/2 GLORIA trial, which is examining a novel combination comprised of NOX-A12, radiotherapy, and bevacizumab in glioblastoma and incomplete tumor resection.

Adjuvant Pembrolizumab Improves DFS in Stage IB-IIIA NSCLC, Irrespective of PD-L1 Expression

January 10th 2022

Adjuvant treatment with pembrolizumab led to a statistically significant and clinically meaningful improvement in disease-free survival vs placebo in patients with stage IB to IIIA non–small cell lung cancer following resection, regardless of PD-L1 expression, meeting 1 of the dual primary end points of the phase 3 KEYNOTE-091 trial.

Pembrolizumab/Pepinemab Combo Safe, Well Tolerated in Advanced, Recurrent, or Metastatic HNSCC

January 7th 2022

The combination of pembrolizumab and pepinemab showcased encouraging safety and tolerability when given as first-line treatment in patients with advanced, recurrent, or metastatic head and neck squamous cell carcinoma.

Novel Immunotherapy Combos Target TIM-3 and PD-1/PD-L1 Networks

January 7th 2022

The immune checkpoint TIM-3 is shaping up to be a viable target for designing therapies for patients with non–small cell lung cancer and other malignancies.

FDA Accepts IND for RM-1995 Photoimmunotherapy in Advanced Cutaneous or Head and Neck SCC

January 6th 2022

The FDA has accepted an investigational new drug application for the photoimmunotherapy treatment, RM-1995, for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.

Tiragolumab Plus Atezolizumab Demonstrates Improvement in PFS, OS, ORR in PD-L1+ NSCLC

January 4th 2022

The addition of tiragolumab to atezolizumab produced a clinically meaningful improvement in progression-free survival, overall survival, and objective response rate compared with atezolizumab alone in the first-line treatment of patients with PD-L1–positive non–small cell lung cancer.

FDA Grants Fast Track Status to Novel Gene Therapy Plus Pembrolizumab for Late-Stage NSCLC

January 3rd 2022

The FDA has granted a fast track designation to a combination comprised of the immunogene therapy quaratusugene ozeplasmia and pembrolizumab for use in select patients with late-stage non–small cell lung cancer.

Immune Checkpoint Inhibitors Extend Survival for Mesothelioma

December 28th 2021

Immune checkpoint inhibitor therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma.

Pembrolizumab Combination Advances Standard of Care in TNBC

December 27th 2021

Peter Schmid, MD, PhD, discussed how this approval defines a new standard of care for patients with TNBC.

Allison Shares His Path to Groundbreaking Achievements in Immuno-Oncology

December 23rd 2021

James P. Allison, PhD, permanently etched his legacy into immuno-oncology with the development of ipilimumab, work that helped him win a Giants of Cancer Care® award for Scientific Advances in 2014.

Dr. Aggarwal the Significance of the IMpower010 Trial in PD-L1+ NSCLC

December 15th 2021

Charu Aggarwal, MD, MPH, discusses the significance of the phase 3 IMpower010 trial in patients with PD-L1–positive non–small cell lung cancer.

Dr. Weber Discusses Unmet Needs in Ocular and Mucosal Melanoma

December 15th 2021

Jeffrey S. Weber, MD, PhD, discusses unmet needs in ocular and mucosal melanoma.

FDA Approves Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma Following CR

December 3rd 2021

The FDA has approved pembrolizumab for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection.

BO-112 Plus Pembrolizumab Improves ORR in Advanced Melanoma After Progression on Anti–PD-1 Therapy

December 1st 2021

The addition of BO-112 to pembrolizumab produced clinical benefit in patients with unresectable malignant melanoma who have experienced disease progression on anti–PD-1 therapy, according to data from the preliminary analysis of the phase 2 SPOTLIGHT-203 trial.

Dr. Allison on the Impact of Immunotherapy in Cancer

November 30th 2021

James P. Allison, PhD, discusses the impact of immunotherapy on patients with cancer.

Dr. Allison on the Development of Ipilimumab for Cancer Treatment

November 30th 2021

James P. Allison, PhD, discusses the development of ipilimumab.

Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson

November 22nd 2021

Dr. Allison highlights everything from his proudest professional moments, to MD Anderson’s Moon Shot program, to his musical talents, to next steps he’s taking in cancer research.